Given its critical role in the pathogenesis of Alzheimer's disease, PSEN1 is considered a potential therapeutic target. Modulating the activity of the gamma-secretase complex to alter the processing of APP and reduce the production of amyloid-beta peptides is a key strategy under investigation. However, given the complex role of PSEN1 in various cellular processes, therapeutic approaches must be carefully designed to avoid unwanted side effects.
